- Home
- ALNY vs LYV Comparison
ALNY vs LYV Comparison
Compare ALNY & LYV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | LYV |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 39.7B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ALNY | LYV |
|---|---|---|
| Price | $224.00 | $169.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 25 |
| Target Price | ★ $370.55 | $202.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.88 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | $1,037,418,000.00 | ★ $25,201,406,000.00 |
| Revenue This Year | $47.60 | $11.58 |
| Revenue Next Year | $26.59 | $9.19 |
| P/E Ratio | $82.59 | ★ N/A |
| Revenue Growth | ★ 22.88 | 8.83 |
| 52 Week Low | $197.81 | $125.34 |
| 52 Week High | $495.55 | $189.25 |
Technical Indicators
Market Signals| Indicator | ALNY | LYV |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 43.72 |
| Support Level | $219.54 | $165.49 |
| Resistance Level | $234.00 | $173.82 |
| Average True Range (ATR) | 8.80 | 3.46 |
| MACD | -1.30 | 0.39 |
| Stochastic Oscillator | 20.76 | 45.63 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About LYV Live Nation Entertainment Inc.
Live Nation is the largest live entertainment company in the world, serving as a concert promoter, venue operator, and ticketing platform. In addition, the firm generates revenue from sponsorships and advertising. With offices in 51 countries, Live Nation promotes concerts globally. It owned, operated, or had exclusive booking rights to more than 400 venues worldwide at the end of 2025, which the firm says makes it the second-largest operator of music venues globally. In 2025, Live Nation promoted nearly 55,000 events, drawing roughly 160 million fans. Ticketmaster is a dominant global ticketing service, selling nearly 650 million tickets in 2025.